NasdaqCM - Nasdaq Real Time Price USD

Petros Pharmaceuticals, Inc. (PTPI)

Compare
0.3298 -0.0204 (-5.83%)
At close: December 13 at 4:00:00 PM EST
0.3202 -0.01 (-2.91%)
After hours: 7:59:44 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for PTPI

Recent News: PTPI

View More
Petros Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Petros Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St. 28 days ago
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
ACCESSWIRE 3 months ago
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
ACCESSWIRE 3 months ago
Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations

Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
Simply Wall St. 3 months ago
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
ACCESSWIRE 4 months ago
Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
ACCESSWIRE 4 months ago
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch
ACCESSWIRE 6 months ago
Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA
ACCESSWIRE 6 months ago
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
ACCESSWIRE 6 months ago
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals

Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
GlobeNewswire 6 months ago
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health

Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
ACCESSWIRE 7 months ago
View More

Related Tickers

BFRI Biofrontera Inc.
1.0600
0.00%
 
SXTC China SXT Pharmaceuticals, Inc.
0.3850
-4.54%
 
CPHI China Pharma Holdings, Inc.
0.1770
-4.58%
 
AKAN Akanda Corp.
1.4900
-4.49%
 
CPIX Cumberland Pharmaceuticals Inc.
2.3800
+9.17%
 
GELS Gelteq Limited
2.7400
-10.16%
 
PRFX PainReform Ltd.
3.1100
+6.51%
 
PROC Procaps Group S.A.
2.4100
+3.88%
 
OPTN OptiNose, Inc.
0.4710
-3.54%
 
YCBD cbdMD, Inc.
0.3908
+0.21%